Goldman Forecasts $160B 2026 IPO Surge, Eikon Therapeutics Among Early Raisers
Goldman Sachs projects U.S. IPO proceeds will quadruple to $160 billion in 2026 while listings double to 120 on stronger equity prices and improved financing conditions. Eikon Therapeutics was among the firms contributing to roughly $5 billion raised in early 2026 IPOs, underscoring robust biopharma investor demand.
1. Goldman Sachs Forecasts $160B IPO Market in 2026
Goldman Sachs projects that U.S. IPO proceeds will quadruple to $160 billion in 2026, with the number of listings expected to double to 120 due to stronger equity prices, improved financing conditions and large private company debuts.
2. Eikon Therapeutics Among Early 2026 IPO Raisers
Eikon Therapeutics debuted as part of a roughly $5 billion haul from early 2026 IPOs alongside Forgent Power Solutions, highlighting robust investor demand for biopharma offerings in the initial wave.